NH Korindo Sekuritas Indonesia
Menu
  • OUR SERVICE
    • News & Research
      • News
      • Equity Report
      • Research Fixed Income
      • Company Report
      • Outlook
      • Special Notation
    • Equity
    • Fixed Income
    • Margin
    • Bonds
    • Investment Banking
      • IPO
      • E-IPO
    • Wealth Management
      • Mutual Funds
    • Download Center
      • Download NAIK
      • Documents
    • Academy
      • Stock Dictionary
      • Stock Education
  • ABOUT US
    • Our Firm
    • Our People
    • Our Branch
    • Corporate Governance
    • Careers
    • FAQ
  • CONTACT
  • Register
  • EN
    • ID
  • ID
  • EN

Kalbe Farma Tbk (KLBF) Stable Growth

  • Author
  • Recent Posts
NHKSI Research Team
NHKSI Research Team
NHKSI Research Team
Latest posts by NHKSI Research Team (see all)
  • Fixed Income News | Obligasi tertekan, ancaman inflasi dari perang dorong imbal hasil naik - April 2, 2026
  • Daily Report | 2 Apr 2026 - April 2, 2026
  • XA Research Short Notes | PT Fore Kopi Indonesia Tbk. (FORE) – Strong FY25 Earnings Driven by Strategic Expansion and Disciplined IPO Fund Utilization - April 1, 2026

Single-Digit Growth in Sales
KLBF is projected to post the growth of 3.4% in 2018’s sales. The growth is a lot lower than the growth of 4.2% in 2017. It aligns the survey disclosing the decline in Indonesia’s retail sales growth from 3.5% in 2017 to 3.03% y-t-d in 2018.

Adjustment to Selling Prices of Pharmaceutical Drugs
The U.S. dollar strengthening further against the rupiah during 2018 leads to the adjustment to selling prices of pharmaceutical drugs by pharmaceutical companies; KLBF has raised the selling prices of its products by 3%-4% in 3Q18, for example.

Download full report HERE.

Share This Article

Related Article


XA Research Short Notes | PT Fore Kopi Indonesia Tbk. (FORE) – Strong FY25 Earnings Driven by Strategic Expansion and Disciplined IPO Fund Utilization

01 Apr 2026

FORE reported a strong FY25 performance with net profit rising to IDR 90.1 billion (+55% YoY).

XA Market Update Report | Fundamentals Say Go, Conditions Say No

31 Mar 2026

We project JCI to begin rebounding back in the 2H26 to the range of 9,500-9,700. We have downgraded our JCI base case from 10,000.

PT Charoen Pokphand Indonesia Tbk. (CPIN) – Earnings Take Flight on Strong Poultry Prices

30 Mar 2026

CPIN delivered a solid FY25 performance, with revenue growing +5% YoY to IDR 70.7 tn. 4Q25 revenue rose +13% YoY (+15% QoQ) to IDR 20.1 tn.

 

More Article

Uncategorized

02 Apr 2026

Fixed Income News | Obligasi tertekan, ancaman ...

Obligasi pemerintah global menuju penurunan bulanan terdalam dalam beberapa tahun terak...

READ MORE

Daily Report

02 Apr 2026

Daily Report | 2 Apr 2026

The JCI closed higher in the green, up 1.93% at 7,184.4, with the next resistance level...

READ MORE

Analysis Report

01 Apr 2026

XA Research Short Notes | PT Fore Kopi Indonesi...

FORE reported a strong FY25 performance with net profit rising to IDR 90.1 billion (+55...

READ MORE

Contact Us

  • Treasury Tower 51th Floor, District 8, SCBD Lot 28, Jl. Jend. Sudirman No.Kav 52-53, RT.5/RW.3, Senayan, Kebayoran Baru, South Jakarta City, Jakarta 12190
  • cso@nhsec.co.id
  • +62 21 5088 9100 (Representative Number)
    +62 21 5088 9102 (CS Number)
  • +628 118 198 111 (Official Whatsapp 1)
    +6281 67 0000 5 (Official Whatsapp 2)

Link

  • Our Firm
  • Research
  • Our People
  • Download
  • Dictionary
  • FAQ

Certified By

Data yang ditampilkan di aplikasi PT NH Korindo Sekuritas Indonesia berasal dari BEI dan telah disetujui untuk ditampilkan.

PT NH Korindo Sekuritas Indonesia berizin dan diawasi oleh Otoritas Jasa Keuangan (OJK).


© Copyright 2026 NH Korindo Sekuritas. All rights reserved.